Centocor to launch Myoscint in Japan this year:
This article was originally published in Clinica
Executive Summary
Centocor, the US biotechnology company based in Malvern, Pennsylvania, will launch its heart attack imaging agent, Myoscint, in Japan in the fourth quarter. In the US the product will reach the market in the first quarter of 1997 following FDA approval in early July.